At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 319 enrolled
Drug / intervention
PF-06651600 or Placebo +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY OF ORAL PF-06651600 AND PF-06700841 AS INDUCTION AND CHRONIC THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
In Brief
A Phase 2 clinical trial evaluating PF-06651600 or Placebo, PF-06700841 or Placebo, and 2 other interventions for Ulcerative Colitis. Completed, enrolled 319 participants across 189 sites in 19 countries.
Detailed Summary
The purpose of this study is to determine whether PF-06651600 and PF-06700841 are effective in treatment of moderate to severe ulcerative colitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUlcerative Colitis
CountriesAustria, Bulgaria, Czechia, Denmark, Georgia, Germany, Hungary, Israel, Italy, Poland, Romania, Russia, Serbia, Slovakia, South Korea, Spain, Turkey (Türkiye), Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartFeb 2017
Primary CompletionMay 2021
TodayJul 2026
First PostedNov 8, 2016
Enrollment StartFeb 3, 2017
Primary CompletionMay 10, 2021
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 9.7 years ago
Interventions
PF-06651600 or Placebodrug
Delivered orally for 8 weeks.
PF-06700841 or Placebodrug
Delivered orally for 8 weeks.
PF-06700841drug
Delivered orally for 24 weeks.
PF-06651600drug
Delivered orally for 24 weeks.